Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron Weekly vs Every 3 Weeks for CINV Prevention
NCT06080880Recruiting
- Sponsor
- Hubei Cancer Hospital
- Start
- Dec 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of ondansetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Hubei Cancer Hospital. Primary endpoint: Complete Response Rate at 6 weeks. Started Dec 2023; status: recruiting.
02
Drugs
ondansetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT06080880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06080880.